Pulse Biosciences Stock Forum

$Pulse Biosciences(PLSE.US)$ Reuters · just 1min.                                                   Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for Cellfx® Nspfa Cardiac Surgery System for the Treatment of Atrial Fibrillation

$Pulse Biosciences(PLSE.US)$ Officer Barrett Burke Thomas purchased 10,000 shares of common stock on May 20, 2024 at an average price of $8.56 for a total value of $85,600.

$Pulse Biosciences(PLSE.US)$ Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
1 MINUTE AGO, 8:00 AM EST
VIA BUSINESSWIRE

$Pulse Biosciences(PLSE.US)$ Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp 1 MINUTE AGO, 8:00 AM EST VIA BUSINESSWIRE

$Pulse Biosciences(PLSE.US)$ Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter 3 MINUTES AGO, 8:00 AM EST VIA BUSINESSWIRE

$Pulse Biosciences(PLSE.US)$ 10% Shareholder DUGGAN ROBERT W purchased 218.6K shares of Common Stocks on Nov 29, 2023 at an average price of $9.38 for a total value of $2.05 million

$Pulse Biosciences(PLSE.US)$ On November 27, 2023, Pulse Biosciences, Inc. (the “Company”) provided the following programmatic updates with respect to its proprietary CellFX nsPFA cardiac catheter and cardiac clamp: CellFX nsPFA Cardiac Catheter ● As of today, the Company has received all regulatory approvals and it has substantially completed all required activities to commence its planned catheter ablation feasibility study. The first study procedures in this clinical trial a...